Is Wegovy affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: GLP1R

Wegovy is affected by pharmacogenetics through the GLP1R gene. Your genotype for this gene can change how your body processes Wegovy, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Moderate, based on CPIC or FDA guidelines.

What's in Wegovy

semaglutide affected by GLP1R

Affected by GLP1R · Gene2Rx · Moderate evidence

Read the full semaglutide genetics guide →

Semaglutide phenotype recommendations

Published guidance from Gene2Rx on how semaglutide should be dosed or substituted based on your GLP1R phenotype.

Phenotype	What it means	Recommendation	Evidence
Typical Response GLP1R	Your genotype suggests a typical response to semaglutide with average efficacy and side-effect risk.	Gene2Rx Standard dosing and titration are expected to produce an average response.	Moderate
Enhanced Response (heterozygous) GLP1R	You may lose slightly more weight on semaglutide than average, with a modestly higher chance of nausea or vomiting.	Gene2Rx Use standard dosing. Counsel on the likelihood of somewhat greater weight loss and slightly higher GI side-effect risk; consider slower titration if early side effects emerge.	Moderate
Enhanced Response (homozygous) GLP1R	You are likely to lose more weight on semaglutide than average, but you also have a higher chance of nausea or vomiting.	Gene2Rx Use standard dosing. Counsel on the likelihood of greater weight loss and higher GI side-effect risk; consider a slower titration schedule to mitigate side effects.	Moderate
Indeterminate GLP1R	We were not able to determine your GLP1R genotype, so we cannot personalize guidance for semaglutide.	Gene2Rx Use standard dosing and titration. Monitor response.	—
Not available GLP1R	We do not have a GLP1R result for you, so we cannot personalize guidance for semaglutide.	Gene2Rx Use standard dosing and titration. Monitor response.	—

Source: Gene2Rx

The gene behind the guidance

GLP1R Glucagon-Like Peptide-1 Receptor

GLP1R is the cell-surface receptor that GLP-1 drugs like semaglutide and tirzepatide bind to. A common variant (rs10305420, Pro7Leu) changes how efficiently the receptor gets made and shipped to the cell surface. Leu7 carriers tend to lose a bit more weight on GLP-1 drugs, but they also get more nausea and vomiting.

Roughly a third of people of European descent carry at least one Leu7 allele. The variant doesn't decide whether a GLP-1 drug will work for someone. It changes how strong the response is and shifts the side-effect profile.

See all drugs affected by GLP1R →

Browse the full drug-class: Weight management (GLP-1 agonists).

Find out how your genetics affect Wegovy

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.